Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
LTR Pharma Limited ( (AU:LTP) ) just unveiled an update.
LTR Pharma Limited has announced a national distribution agreement with Symbion, a major pharmaceutical wholesaler in Australia, to enhance the distribution of its product SPONTAN®. This strategic partnership, which will begin in March 2025, will leverage Symbion’s expansive network to provide warehousing, inventory management, and distribution services to over 3,900 pharmacies nationwide. By integrating key operational systems, this collaboration aims to support LTR’s early access scheme and establish a foundation for the full commercial launch of SPONTAN®, positioning LTR Pharma for significant growth in the men’s health market.
More about LTR Pharma Limited
LTR Pharma is focused on improving men’s health, both physically and mentally, by commercializing an innovative nasal spray treatment for Erectile Dysfunction (ED). Their lead product, SPONTAN®, utilizes intranasal delivery technology of a PDE5 inhibitor, allowing for rapid drug absorption and action within 10 minutes, thereby enhancing the spontaneity and enjoyment of sexual experiences.
YTD Price Performance: -17.28%
Average Trading Volume: 723,686
Technical Sentiment Consensus Rating: Strong Buy
See more data about LTP stock on TipRanks’ Stock Analysis page.
